Alector, Inc. (ALEC)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Alector, Inc. keeps $77 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Revenue directionally wasn’t disclosed in Alector’s preliminary third fiscal quarter of 2026 update reported November 5, 2026, but the release did provide a cash-flow snapshot, with negative operating cash flow of roughly $24.2 million as the company continues funding its immuno-neurology biotechnology pipeline. No EPS or net income figure was provided in the preliminary results, and no consensus comparison was given. Looking ahead, consensus for the next period calls for EPS of $0.29 on revenue of $77.8 million.
About Alector, Inc.
Alector, Inc. is a NASDAQ-listed Biotechnology company focused on immuno-neurology, developing therapies that address immune dysfunction in degenerative brain disorders. In FY2025, it generated $21.0 million in revenue. The company works at the intersection of neuroscience and the innate immune system, aiming to change how neurodegenerative disease is treated.
Today's Snapshot
The day ended with ALEC slightly higher at 2.57, while its sector was weaker.
Trading Volume
Above 10d avg 2.1M
2.1M
vs S&P 500 Today
Outperforming Market
+0.65%
Updated: November 18, 2026 at 21:20 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$2.00 - $2.47Buy
- RSI (14)62.64Neutral
- Stochastic %K (14, 3, 3)66.67Neutral
- MACD Level (12, 26)0.15Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.